Dr Abla talks to ecancertv at ASH 2015 about an international, retrospective study looking at the incidence of and predictors for early death in paediatric patients with acute promyelocytic leukaemia (APL).

APL is a rare subtype of acute myeloid leukaemia (AML) in children, Dr Abla explains and although the prognosis for those affected has improved over the years, a small proportion of children still die very early on in the disease course.

The study considered data on more than 700 children and found the overall incidence of early death was 6.3%.

Results support the early oral use of all-trans retinoic acid (ATRA), Dr Abla suggests.

University Hospital pediatric doctors treating new subtype of Leukemia

Join panellists Dr Peter Diamond, Associate Professor Rishi Kotecha, Dr Laurence Cheung and Nicole Sherlock to learn more about all the work being done to help save the lives of young Australians with blood cancer.

During the 2021 ASCO Annual Meeting, the AML Hub spoke with Hui Zhang, Guangzhou Women and Children's Medical Center, Guangzhou, CN. We asked, How efficacious is CAR-T in childhood AML?

Zhang begins by outlining novel approaches to improve prognosis in relapsed/refractory patients, highlighting the increasing role of CAR T-cell therapy in pediatric AML. He then describes the encouraging results and response rates of his project, presented at ASCO. Finally, Zhang discusses which patients might benefit from CAR T-cell therapy, such as those who are unresponsive to tyrosine kinase inhibitors (TKIs).

Pediatric leukemias have been a success story in the history of cancer management. Proper evaluation and treatment can cure most of the patient. It is important to know the specific protocol for such treatments. Dr Amita Mahajan, Senior Consultant Pediatric Hematologist and Oncologist has extensively discussed about current management perspective of such malignancies with special emphasis on role of radiation in those patients.